What is the trial about?

The Celeste Light for PD Trial features a non-invasive device that recently
received Breakthrough Device designation from the FDA for treating Parkinson’s disease.

If this trial is successful, Celeste could make a major difference in managing non-motor symptoms and improving overall function on top of current best medical care.

Participants from anywhere across the country with an internet connection
can apply and will be evaluated via video conference in the most natural and accurate setting — their homes. The trial features a specialized light therapy device that should be used daily for one hour in the evening for six months. Participants can do normal activities like sitting, watching TV, eating, reading, or using a computer while using the Celeste device.

The device is convenient, non-invasive, and can be used with current medical care. The device is safe to use, and the trial will not increase the risk for COVID-19 infection. The treatment is a minimal risk.

Who’s running the trial?

The Celeste Light for PD trial is a partnership between
the Center for Health + Technology at the University of Rochester (CHeT) and PhotoPharmics.

CHeT designs and conducts multi-center clinical trials with collaborators from across the globe
to accelerate clinical research and advance the development of therapeutics, benefiting individuals
in the Parkinson’s community and beyond. Since its inception over three decades ago, CHeT has reshaped the conduct of clinical trials, from incorporating novel technologies into clinical trial design to modeling disease progression. Learn more at chet.urmc.edu.

PhotoPharmics is a privately held, clinical-stage medical device company developing
next-generation treatments for treating neurodegenerative diseases. The founders of the company have
30+ years of research and experience in this field and have previously developed specialized light solutions now widely used to regulate circadian rhythms in seasonal affective disorder, sleep disorders, anxiety, and depression (acquired by Philips-Respironics in 2007).

Drawing from research and recent trials, PhotoPharmics is developing applications of
specialized light across several neurodegenerative diseases. The company aims to make a
clinically meaningful difference in patients’ lives by delivering safe and effective
non-invasive treatments. Investor inquiries are welcomed.
Learn more at www.photopharmics.com.